Armata Pharmaceuticals, Inc. (ARMP)Stock Price & Financial Statements
AboutArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.Show more
- Revenue $5M +14.2%
- EBITDA -$41M -3.0%
- Net Income -$19M +72.6%
- EPS (Diluted) -0.52 +72.6%
- Gross Margin -565.37% -819.9%
- EBITDA Margin -794.57% +9.9%
- Operating Margin -820.18% +9.2%
- Net Margin -365.6% +76.0%
- ROE -
- ROIC -44.21% -4.4%
- Debt/Equity -
- Interest Coverage -3.95 +74.6%
Key Insights
Based on financial data analysisStrengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓High quality earnings: Operating CF exceeds net income
Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y28.89%
5Y-
3Y4.96%
TTM-7.55%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-13.39%
EPS CAGR
10Y-
5Y-
3Y-
TTM19.15%
ROCE
10Y Avg-84.25%
5Y Avg-59.96%
3Y Avg-56.74%
Latest-70.67%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
 TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
 AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
 MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
 PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare ARMP vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 475K | 260K | 115K | 0 | 0 | 823K | 4.47M | 5.51M | 4.53M | 5.17M |
| Revenue Growth % | 16.14% | -45.26% | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% |
| Cost of Goods Sold | 0 | 369K | 374K | 1.35M | 1.35M | 14.44M | 20.02M | 35.02M | 972K | 34.43M |
| COGS % of Revenue | - | 141.92% | 325.22% | - | - | 1755.04% | 447.36% | 635.75% | 21.46% | 665.37% |
| Gross Profit | 475K | -109K | -259K | -1.35M | -1.35M | -13.62M | -15.54M | -29.51M | 3.56M | -29.25M |
| Gross Margin % | 100% | -41.92% | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% |
| Gross Profit Growth % | 16.14% | -122.95% | -137.61% | -421.62% | 0% | -908.22% | -14.1% | -89.88% | 112.05% | -922.38% |
| Operating Expenses | 10.7M | 23.64M | 16.27M | 9.54M | 17.74M | 7.97M | 8.28M | 7.44M | 44.45M | 13.18M |
| OpEx % of Revenue | 2253.05% | 9091.54% | 14148.7% | - | - | 967.92% | 185.09% | 135.02% | 981.39% | 254.81% |
| Selling, General & Admin | 6.42M | 8.41M | 7.59M | 5.7M | 7.91M | 7.97M | 8.28M | 7.44M | 10.68M | 13.18M |
| SG&A % of Revenue | 1351.79% | 3235.77% | 6600% | - | - | 967.92% | 185.09% | 135.02% | 235.75% | 254.81% |
| Research & Development | 3.99M | 5.68M | 2.88M | 4.89M | 9.82M | 14.44M | 20.02M | 35.02M | 33.77M | 34.43M |
| R&D % of Revenue | 840.42% | 2183.85% | 2505.22% | - | - | 1755.04% | 447.36% | 635.75% | 745.64% | 665.37% |
| Other Operating Expenses | 289K | -554K | 6K | -1.4M | 0 | -14.44M | -20.02M | -35.02M | 0 | -34.43M |
| Operating Income | -10.23M | -23.38M | -16.16M | -12.52M | -19.09M | -21.59M | -23.82M | -36.95M | -40.89M | -42.44M |
| Operating Margin % | -2153.05% | -8991.54% | -14048.7% | - | - | -2622.96% | -532.45% | -670.77% | -902.85% | -820.18% |
| Operating Income Growth % | 27.52% | -128.59% | 30.89% | 22.48% | -52.42% | -13.09% | -10.35% | -55.09% | -10.67% | -3.78% |
| EBITDA | -9.9M | -23.01M | -15.78M | -11.17M | -17.74M | -20.47M | -22.65M | -36.05M | -39.92M | -41.11M |
| EBITDA Margin % | -2083.58% | -8849.62% | -13723.48% | - | - | -2487.61% | -506.33% | -654.58% | -881.39% | -794.57% |
| EBITDA Growth % | 29.06% | -132.48% | 31.41% | 29.2% | -58.76% | -15.42% | -10.65% | -59.16% | -10.72% | -2.99% |
| D&A (Non-Cash Add-back) | 330K | 369K | 374K | 1.35M | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M |
| EBIT | -10.23M | -13.83M | -10.36M | -10.89M | -18.55M | -21.55M | -23.09M | -36.95M | -66.42M | -42.44M |
| Net Interest Income | 0 | 0 | 0 | 0 | -835K | -600K | -59K | 0 | -2.45M | -10.04M |
| Interest Income | 0 | 0 | 0 | 0 | 96K | 28K | 5K | 29K | 179K | 697K |
| Interest Expense | 0 | 0 | 0 | 0 | 931K | 628K | 64K | 29K | 2.63M | 10.74M |
| Other Income/Expense | 9.64M | 3.98M | 2.02M | 956K | -390K | -594K | 667K | 29K | -28.16M | 23.52M |
| Pretax Income | -589K | -19.39M | -14.14M | -16.7M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M |
| Pretax Margin % | -124% | -7459.23% | -12295.65% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% |
| Income Tax | -73K | -556K | -1.3M | -328K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 87.61% | 97.13% | 90.79% | 72.51% | 100% | 100% | 100% | 100% | 100% | 100% |
| Net Income | -516K | -18.84M | -12.84M | -12.11M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M |
| Net Margin % | -108.63% | -7245.38% | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% |
| Net Income Growth % | -102.23% | -3550.78% | 31.85% | 5.67% | -60.85% | -13.87% | -4.39% | -59.43% | -87.03% | 72.6% |
| Net Income (Continuing) | -516K | -18.84M | -12.84M | -16.7M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -278.60 | -345.80 | -27.34 | -8.90 | -2.43 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 |
| EPS Growth % | 14.59% | -24.12% | 92.09% | 67.45% | 72.7% | 44.44% | 28.89% | -12.5% | -76.85% | 72.61% |
| EPS (Basic) | -278.60 | -345.80 | -28.14 | -8.90 | -2.43 | -1.35 | -0.96 | -1.08 | -1.91 | -0.52 |
| Diluted Shares Outstanding | 38.65K | 70.28K | 456.24K | 1.36M | 8.01M | 16.41M | 24.1M | 34.29M | 36.08M | 36.16M |
| Basic Shares Outstanding | 38.65K | 70.28K | 456.25K | 1.36M | 7.83M | 16.41M | 24.1M | 34.29M | 36.08M | 36.16M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.02M | 6.36M | 5.38M | 8.41M | 6.66M | 10.85M | 14.99M | 27.05M | 19.15M | 11.31M |
| Cash & Short-Term Investments | 9.37M | 5.71M | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M |
| Cash Only | 9.37M | 5.71M | 5.13M | 8.16M | 6.03M | 9.65M | 10.29M | 14.85M | 13.52M | 9.29M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 125K | 25K | 0 | 0 | 0 | 561K | 2.99M | 1.94M | 3.36M | 744K |
| Days Sales Outstanding | 96.05 | 35.1 | - | - | - | 248.8 | 243.85 | 128.29 | 271.03 | 52.49 |
| Inventory | 0 | -619K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 521K | 602K | 253K | 0 | 622K | 0 | 0 | 10.26M | 2.27M | 1.27M |
| Total Non-Current Assets | 21.48M | 11.84M | 5.75M | 3.48M | 18.8M | 28.67M | 54.77M | 80.83M | 79.21M | 75.13M |
| Property, Plant & Equipment | 1.13M | 1.07M | 816K | 503K | 4.21M | 12.84M | 38.07M | 46.65M | 57.28M | 54.93M |
| Fixed Asset Turnover | 0.42x | 0.24x | 0.14x | - | - | 0.06x | 0.12x | 0.12x | 0.08x | 0.09x |
| Goodwill | 7.56M | 0 | 0 | 0 | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M | 3.49M |
| Intangible Assets | 12.78M | 10.77M | 4.94M | 2.98M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M | 10.26M |
| Long-Term Investments | 0 | 0 | 0 | 800K | 700K | 1.2M | 0 | 5.96M | 0 | 5.48M |
| Other Non-Current Assets | 0 | 0 | 0 | 136K | 135K | -2.13M | 2.96M | 2.43M | 8.19M | 975K |
| Total Assets | 31.49M | 18.2M | 11.14M | 11.89M | 25.45M | 39.52M | 69.77M | 107.88M | 98.36M | 86.44M |
| Asset Turnover | 0.02x | 0.01x | 0.01x | - | - | 0.02x | 0.06x | 0.05x | 0.05x | 0.06x |
| Asset Growth % | 10.05% | -42.23% | -38.79% | 6.72% | 114.11% | 55.26% | 76.56% | 54.62% | -8.82% | -12.12% |
| Total Current Liabilities | 2.38M | 3.58M | 1.97M | 2.57M | 4.88M | 6.71M | 4.81M | 24.87M | 16.46M | 48.25M |
| Accounts Payable | 1.04M | 1.06M | 578K | 729K | 547K | 956K | 1.14M | 6.03M | 1.58M | 766K |
| Days Payables Outstanding | - | 1.04K | 564.09 | 196.95 | 147.78 | 24.16 | 20.75 | 62.9 | 595.19 | 8.12 |
| Short-Term Debt | 0 | 803K | 0 | 0 | 1.31M | 722K | 0 | 17.01M | 0 | 38.95M |
| Deferred Revenue (Current) | 245K | 933K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 420K | 826K | 340K | 1.35M | 1.7M | 1.94M | 0 | 0 | 1.29M | 529K |
| Current Ratio | 4.20x | 1.78x | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x |
| Quick Ratio | 4.20x | 1.95x | 2.74x | 3.27x | 1.36x | 1.62x | 3.11x | 1.09x | 1.16x | 0.23x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 16.39M | 4.89M | 1.44M | 841K | 5.98M | 13.95M | 39.56M | 46.92M | 113.97M | 86.21M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 82.31M | 55.44M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.55M | 10.88M | 36.48M | 31.8M | 28.58M | 27.69M |
| Deferred Tax Liabilities | 3M | 2.45M | 1.15M | 819K | 3.08M | 3.08M | 3.08M | 15.12M | 3.08M | 3.08M |
| Other Non-Current Liabilities | 13.39M | 2.44M | 292K | 22K | 1.35M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 18.78M | 8.47M | 3.41M | 3.41M | 10.86M | 20.66M | 44.37M | 71.8M | 130.43M | 134.46M |
| Total Debt | 0 | 803K | 0 | 0 | 2.86M | 13.15M | 37.99M | 48.81M | 120.37M | 126.52M |
| Net Debt | -9.37M | -4.91M | -5.13M | -8.16M | -3.17M | 3.5M | 27.7M | 33.96M | 106.85M | 117.22M |
| Debt / Equity | - | 0.08x | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -20.50x | -34.37x | -372.22x | -1274.00x | -15.57x | -3.95x |
| Total Equity | 12.71M | 9.72M | 7.73M | 8.47M | 14.59M | 18.86M | 25.4M | 36.08M | -32.06M | -48.02M |
| Equity Growth % | 269.92% | -23.53% | -20.49% | 9.61% | 72.21% | 29.22% | 34.68% | 42.06% | -188.87% | -49.76% |
| Book Value per Share | 328.94 | 138.36 | 16.94 | 6.23 | 1.82 | 1.15 | 1.05 | 1.05 | -0.89 | -1.33 |
| Total Shareholders' Equity | 12.71M | 9.72M | 7.73M | 8.47M | 14.59M | 18.86M | 25.4M | 36.08M | -32.06M | -48.02M |
| Common Stock | 59K | 165K | 95K | 323K | 99K | 187K | 271K | 361K | 361K | 362K |
| Retained Earnings | -362.52M | -381.36M | -394.21M | -406.32M | -157.52M | -179.7M | -202.86M | -239.77M | -308.82M | -327.74M |
| Treasury Stock | 0 | 0 | -401.84M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.49M | -18.2M | -11.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -9.78M | -10.59M | -9.19M | -9.38M | -15.58M | -18.27M | -23.57M | -32.48M | -47.42M | -37.55M |
| Operating CF Margin % | -2059.16% | -4072.69% | -7993.04% | - | - | -2219.93% | -526.93% | -589.71% | -1047.1% | -725.76% |
| Operating CF Growth % | 22.2% | -8.26% | 13.19% | -2.07% | -66.08% | -17.25% | -29.04% | -37.78% | -46% | 20.82% |
| Net Income | -516K | -18.84M | -12.84M | -12.11M | -19.48M | -22.18M | -23.16M | -36.92M | -69.05M | -18.92M |
| Depreciation & Amortization | 330K | 369K | 374K | 389K | 1.35M | 1.11M | 1.17M | 892K | 972K | 1.32M |
| Stock-Based Compensation | 483K | 2M | 700K | 478K | 4.27M | 3.48M | 2.88M | 0 | 938K | 2.89M |
| Deferred Taxes | -73K | -556K | -1.3M | -328K | -454K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -9.85M | 5.77M | 4.33M | 1.84M | 918K | 196K | -1.25M | 3.1M | 29.36M | -20.75M |
| Working Capital Changes | -158K | 670K | -457K | 345K | -2.19M | -874K | -3.22M | 439K | -9.65M | -2.1M |
| Change in Receivables | -25K | 100K | 381K | 0 | 0 | -467K | -2.43M | 1.05M | 0 | 0 |
| Change in Inventory | 0 | 105K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 296K | 298K | -838K | 343K | -1.37M | 544K | 184K | 3.67M | 39K | -3.75M |
| Cash from Investing | -210K | -279K | -58K | -44K | 2.88M | -824K | -1.3M | -2.21M | -8.13M | -1.88M |
| Capital Expenditures | -210K | -279K | -58K | -44K | -131K | -824K | -1.3M | -2.21M | -8.14M | -1.88M |
| CapEx % of Revenue | 44.21% | 107.31% | 50.43% | - | - | 100.12% | 29.15% | 40.14% | 179.82% | 36.32% |
| Acquisitions | 0 | 0 | 0 | 65K | 3.01M | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -1.91M | 9.69M | 0 | 0 | 0 | 0 | 10K | 0 |
| Cash from Financing | 12.78M | 7.21M | 8.67M | 12.45M | 8.97M | 23.21M | 25.52M | 44.02M | 53.99M | 34.96M |
| Debt Issued (Net) | 0 | -100K | -815K | 0 | 0 | 717K | 0 | 0 | 54.03M | 34.89M |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 5K | 130K |
| Dividends Paid | 0 | -80K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 396K | 13K | 133K | 203K | -1M | -400K | -801K | -500K | -43K | -61K |
| Net Change in Cash | 2.79M | -3.66M | -579K | 3.02M | -3.73M | 4.12M | 639K | 4.56M | -1.57M | -4.47M |
| Free Cash Flow | -9.99M | -10.87M | -9.25M | -9.43M | -15.71M | -19.09M | -24.88M | -34.69M | -55.57M | -39.43M |
| FCF Margin % | -2103.37% | -4180% | -8043.48% | - | - | -2320.05% | -556.08% | -629.85% | -1226.92% | -762.08% |
| FCF Growth % | 27.46% | -8.78% | 14.89% | -1.9% | -66.7% | -21.52% | -30.3% | -39.44% | -60.17% | 29.04% |
| FCF per Share | -258.49 | -154.65 | -20.27 | -6.93 | -1.96 | -1.16 | -1.03 | -1.01 | -1.54 | -1.09 |
| FCF Conversion (FCF/Net Income) | 18.96x | 0.56x | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -6.39% | -167.92% | -147.11% | -149.46% | -168.89% | -132.62% | -104.65% | -120.1% | -3439.35% | - |
| Return on Invested Capital (ROIC) | -7670.25% | -429.8% | -326.87% | -644.24% | -243.9% | -95.85% | -47.36% | -45% | -42.35% | -44.21% |
| Gross Margin | 100% | -41.92% | -225.22% | - | - | -1655.04% | -347.36% | -535.75% | 78.54% | -565.37% |
| Net Margin | -108.63% | -7245.38% | -11163.48% | - | - | -2695.14% | -517.55% | -670.24% | -1524.51% | -365.6% |
| Debt / Equity | - | 0.08x | - | - | 0.20x | 0.70x | 1.50x | 1.35x | - | - |
| Interest Coverage | - | - | - | - | -20.50x | -34.37x | -372.22x | -1274.00x | -15.57x | -3.95x |
| FCF Conversion | 18.96x | 0.56x | 0.72x | 0.77x | 0.80x | 0.82x | 1.02x | 0.88x | 0.69x | 1.99x |
| Revenue Growth | 16.14% | -45.26% | -55.77% | -100% | - | - | 443.62% | 23.11% | -17.77% | 14.24% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics